AstraZeneca hit by patent expiries as sales slump
Drugmaker AstraZeneca has showed it is still languishing in intensive care after patent expiries triggered an 8 per per cent fall in sales to $25.7
Despite new chief executive Pascal Soriot’s recent string of acquisitions to boost Astra’s pipeline, the pharmaceuticals giant admitted that it expects revenues to fall again this year by “a low-to-mid-single-digit percentage”.
Astra is suffering from blockbuster drugs, including cholesterol-buster Crestor and heartburn and ulcer treatment Nexium, facing cheaper, generic competition in Australia and Europe respectively.
Those patent expiries, as well as the cost of acquisitions, including spending up to $4.1 billion buying out rival Bristol-Myers Squibb’s stake in a diabetes-medicine development venture, saw Astra’s pre-tax profit crash 57 per cent to $3.3 billion in 2013.
In the crucial United States market, Astra’s revenues fell 7 per cent in the last three months of 2013, while in Europe, where treatments including anti-psychotic drug Seroquel IR dropped out of patent, sales lost 2 per cent in the same period.
The US picture is set to worsen this year: from May, Nexium will face generic competition. Astra admitted that US healthcare reforms, which force drugmakers to pay annual fees, had cost $318 million in the fourth quarter.
Soriot, who has cut Astra’s headcount by more than 11,000 over two years, said: “Our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands. In the near term these headwinds will remain challenging, however I am confident that we can return to growth… and expect our 2017 revenues will be broadly in line with 2013.”
He also said Astra’s late-stage pipeline of drugs that are close to being put forward for regulatory approval has nearly doubled.
The shares fell 3.5%, or 135.5p, to 3741.5p.
- 1 Universities aren't working us hard enough, say undergraduates
- 2 Lego letter from the 1970s still offers a powerful message to parents 40 years later
- 3 To help fuel their propaganda machine against the poor, our government has now decided to redefine the word 'welfare'
- 4 Woman opens professional cuddling shop – gets 10,000 customers in first week
- 5 Grayson Perry: London needs affordable housing because 'rich people don't create culture'
Oscar Pistorius terrorised Reeva before he shot her dead, says June Steenkamp
Audacious North Korean kidnap plot foiled at Paris airport as 'Asian men' attempted to bundle student onto plane
Heroin to be prescribed to Canadian addicts by doctors
Tower Bridge glass walkway 'smashed' by night-time visitor dropping bottle of beer
Revealed: the case against Bill Cosby – through the stories of his accusers
Rochester by-election: Ukip gains second MP as Tory defector Mark Reckless holds seat
'Beast of Bolsover' Dennis Skinner takes Ukip MP Mark Reckless to task moments after he is sworn in
Rochester by-election: Labour MP Emily Thornberry resigns after posting white van and England flags tweet
France 'blocks' Russian sailors from boarding a warship
Rochester aftermath: Sacking of Emily Thornberry will make work of Labour MPs '10 times harder'
Exclusive: UK approved £7m Israeli arms sales in six months before Gaza conflict
iJobs Money & Business
$80000 - $110000 per annum, Benefits: Bonus and Employee Investment Scheme: Se...
€30000 - €50000 per annum, Benefits: Competitive Bonus: Selby Jennings: Java D...
$60000 - $90000 per annum, Benefits: Competitive Bonus and Employee Investment ...
circa 65,000 EUR + Bonus + Benefits: Selby Jennings: Recruiting a Sales Associ...